Dr. Reddy's Laboratories Limited (RDY)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
68.89-0.45 (-0.65%)
As of 2:03PM EST. Market open.
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 69.34 |
| Open | 69.35 |
| Bid | 68.82 x 800 |
| Ask | 68.86 x 800 |
| Day's Range | 68.50 - 69.25 |
| 52 Week Range | 33.33 - 73.50 |
| Volume | 135,032 |
| Avg. Volume | 154,666 |
| Market Cap | 11.475B |
| Beta (5Y Monthly) | 0.00 |
| PE Ratio (TTM) | 49.07 |
| EPS (TTM) | 1.40 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.33 (0.48%) |
| Ex-Dividend Date | Jul 10, 2020 |
| 1y Target Est | 69.82 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-11% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Zacks
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
- Business Wire
Dr. Reddy’s Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
- Business Wire
Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.
© 2021 Verizon Media. All rights reserved.
